TheEdgeResearch
Home / Stocks / ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ Healthcare Biotechnology
$0.19 ▼ -3.52%
Market Cap
$13.5M
Sector
Healthcare
Industry
Biotechnology
Beta
0.33
52-Wk Range
0.16-3.6
CEO
Daniel J. O'Connell
Country
US
Currency
USD

Acumen Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Newton, MA, US. The stock last traded at $0.19, down 3.52% on the session, giving a market capitalisation of $13.5M. On trailing twelve-month figures it carries a trailing P/E of -0.12, a net margin of 0.0%. Its beta of 0.33 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.12
Price / Sales
0.00
Price / Book
0.39
EV / EBITDA
0.13
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.76
Current ratio
1.89
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
61
IPO date
2021-07-01
Headquarters
Newton, MA, US
About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Comparable companies

Acumen Pharmaceuticals, Inc. is most often compared with the following Healthcare names:

ACTUAGENALECFATEINOIRDMCRBSEERSPROVTGN
More research on ABOS
ABOS technical analysis ABOS TheEdge Score Compare against peers
Open full interactive analysis & DCF →